MRK241101P155000
- 0.00
- 0.000.00%
Merck & Co Newsroom
Jim Cramer Thinks That Merck & Co., Inc. (MRK) Is 'Too Low'
Nasdaq Hits Record High While Wed Earnings Are Mixed | Wall Street Today
A Look Into Merck & Co Inc's Price Over Earnings
Unusual Options Activity: MRK, W and Others Attract Market Bets, MRK V/OI Ratio Reaches 206.5
Tuesday Market Falls on Tough Earnings, With AMD and Alphabet Reporting Tonight | Live Stock
Merck KGaA Plans EUR70 Million Investment at US Facility
Slow Day to Start Busy Week | Wall Street Today
Market Climbs as Investors Prepare for Biggest Earnings Week of the Year | Live Stock
Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 (MRNA-4157) in Combination With KEYTRUDA (Pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients With Certain Types of Non-Small Cell Lung Cancer (NSCLC)
Express News | Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 (Mrna-4157) in Combination With Keytruda® (Pembrolizumab) After Neoadjuvant Keytruda and Chemotherapy in Patients With Certain Types of Non-Small Cell Lung Cancer (Nsclc)
Merck & Co., Inc. (MRK): Among the Best Dow Stocks to Buy According to Analysts
About 75% of Companies That Reported Earnings This Week Delivered EPS Wins-Earnings Scorecard
Earnings Preview: Merck & Co to Report Financial Results Pre-market on October 31
Weekly Buzz: Is Tesla a sign of earnings to come?
BetterInvesting Magazine Update on Merck (MRK) and Ball (BALL)
Friday Market Falls With Busy Business Ahead | Wall Street Today
Catalyst Watch: Eyes on Tech With Apple, Amazon, Alphabet, and Meta Reporting
Merck Is Maintained at Buy by Citigroup
Merck & Co Analyst Ratings
IBRX Soars 47% on Initial Trials For Cell Therapy Product